ERCC5 RS751402

CI-VAR-00003955Explore in graph →ClinVar 310903 CIViC 255 rs751402

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Parietal Lobe Ependymoma1unmapped disease
ERCC5 RS751402	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID665 The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies. 55 post-operativ… (full text at CIViC) PMID 26338418 · Somers et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
310903	Benign	criteria provided, multiple submitters, no conflicts	2	Xeroderma pigmentosum, group G	germline	3	Nov 11, 2018	clinvar